Clinical Report: Dupilumab Faces Trial in Chronic Hives

Overview

Dupilumab demonstrated significant reductions in itch severity and overall urticaria activity compared to placebo in patients with chronic spontaneous urticaria (CSU) unresponsive to antihistamines, as shown in the LIBERTY-CSU CUPID-C trial. The findings suggest dupilumab may offer a new treatment option for this challenging condition.

Background

Chronic spontaneous urticaria (CSU) affects approximately 0.5% to 1% of the global population and can severely impact quality of life. Standard treatments, primarily histamine 1-receptor antagonists, are effective in only about half of patients, leaving many symptomatic. The introduction of dupilumab represents a potential advancement in managing CSU, particularly for those who remain symptomatic despite conventional therapies.

Data Highlights

Key Findings

• Dupilumab produced greater reductions in itch severity compared to placebo at week 24 (p<0.05).
• 70% of dupilumab patients achieved at least a 5-point reduction in itch severity versus 52% in the placebo group (p<0.05).
• 41% of dupilumab-treated patients achieved well-controlled disease activity compared to 23% with placebo (p<0.05).
• In pooled analyses, dupilumab showed consistent improvements in itch and urticaria activity scores.
• Safety profiles were similar between dupilumab and placebo groups, with common adverse events including nasopharyngitis and injection-site reactions.

Clinical Implications

Dupilumab may provide a new therapeutic option for patients with CSU who do not respond adequately to antihistamines. Clinicians should consider this treatment for patients with severe symptoms, particularly those with a history of inadequate response to standard therapies, while being aware of potential side effects.

Conclusion

The findings from the LIBERTY-CSU CUPID-C trial support the efficacy of dupilumab in managing chronic spontaneous urticaria, indicating its potential role in treatment algorithms for this condition.

References

1. Conexiant, Conexiant, 2025 -- Dupilumab Gains Pediatric CSU Approval
2. Conexiant, Conexiant, 2025 -- Dupilumab and Lymphoma Risk in AD?
3. Springer, Dermatology and Therapy, 2025 -- Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis
4. JAMA Network, JAMA Dermatology, 2025 -- Chronic Spontaneous Urticaria
5. PubMed, PubMed, 2025 -- Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials
6. Retinal Physician — Clinical Trial Spotlight
7. Chronic Spontaneous Urticaria | Allergy and Clinical Immunology
8. Dupilumab in Patients With Chronic Spontaneous Urticaria
9. Biological and target synthetic treatments for chronic spontaneous urticaria: A systematic review and network meta-analysis - PubMed